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The Importance of Epidemiological Studies
and BeyondMasafumi Kitakaze, MD, PHDL ongevity is a positive consequence of the bat-tle against cardiovascular disease (CVD) (1);however, attempts to decrease the incidence
of CVD or the prevalence of its risk factors have
been in vain. Metabolic syndrome, or its components
such as hypertension, dyslipidemia, and diabetes,
have been recognized as independent potential risk
factors for CVD (2). The prevalence of these factors
seems to have decreased in the United States and
Europe but has seemingly increased in Asia, espe-
cially in Japan.
To respond to this unfavorable trend, the Japa-
nese government launched the National Health
Promotion Movement in the 21st Century (Health
Japan 21) between 2001 and 2012. The major targets
in the ﬁeld of CVD are: 1) reduction of salt intake;
2) promotion of exercise; and 3) reduction of the
prevalence of diabetes, hypertension, dyslipidemia,
smoking, and metabolic syndrome. For >10 years,
this movement decreased the prevalence of high
blood pressure only, whereas other factors remained
unchanged or even worsened. This resulted in un-
changed mortality due to coronary artery disease
(CAD). In addition, according to NIPPON DATA
(National Integrated Project for Prospective Obser-
vation of Non-communicable Disease and its Trends
in the Aged) (3), the prevalence of hypertension in
men and women in 2010 remained high at 62% and
48%, respectively; among the hypertensive popula-
tion who were compliant with medications, the
prevalence was lower at 32% and 40%, respectively.
When these proportions of hypertensive subjectslinical Medicine and Development, National
ar Center, Suita, Japan.are compared with that of the baseline survey in
1980 (50.5% for men and 41.4% for women) (4), it
appears that Health Japan 21 was not successful in
reducing the prevalence of hypertension. This
increasing incidence was also observed in China,
although the absolute values were less than those in
Japan (5). In fact, a total of 26.6% Chinese adults
had hypertension in 2007 to 2008, with a higher
prevalence in men and women at 29.2% and 24.1%,
respectively, when compared with 20% and 17%,
respectively, in 2002 (6). This resulted in a cardio-
vascular (CV) mortality of 240 per 100,000 persons
in China (7).
SUCCESS AND FAILURE TO CONQUER
CV EVENTS IN THE UNITED STATES AND ASIA
These recent trends in the prevalence of CV risk
factors in Asia are completely different from those in
the United States or Europe (8). In the United States,
the rates of hypertension did not change between
1999 and 2000 (28.5%) and 2007 and 2008 (29.0%).
This resulted in a decline in CAD-associated mor-
tality by approximately one-half (542.9 to 266.8
deaths per a population of 100,000) from 1980 to
2000; this decline was attributed to reductions in
the prevalence of major risk factors and the promo-
tion of evidence-based medical therapies (9). On the
contrary, CV deaths in Japan have increased from
143 to 156 per a population of 100,000 in 2009 and
2012, respectively (10). The reason for this low ab-
solute value of CV death in Japan is not entirely
clear, but it may be attributable to differences in the
deﬁnitions of CV death, the social or health insur-
ance system, and the prevalence of other risk fac-
tors. Interestingly, the prevalence of diabetes and
other potential CV risk factors was 6% in 2005 and
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1977% to 8% in 2008 in the United States (11), 5.5% in
2000 to 2002 in Japan (12), and 11.6% in 2010 in China
(13), although epidemiologists and diabetes special-
ists in Japan predict that the prevalence of diabetes
would further increase in the future. Therefore, the
prevalence of risk factors or CVD per se is increasing
in Asia, especially in Japan, compared with that
of Western countries. On top of this trend is the
increasing majority of the aged population in Japan,
and because aging is the most important risk for CVD,
the CV crisis is expected to increase further. Because
these trends and their mechanisms could not be
precisely investigated by basic or clinical studies,
a worldwide epidemiological analysis should be




For 10 years, our group has worked on a resident-
based cohort study at Arita-cho in Saga, Japan, and
found that the prevalence of hypertension, diabetes,
dyslipidemia, metabolic syndrome, and current
smoking in 2005 were 42%, 7%, 37%, 19%, and 14%,
respectively (14). We also found that plasma B-type
natriuretic peptide (BNP) levels can predict the
10-year risk for CAD and may be considered for in-
clusion in the recommendations for a comprehensive
annual health care check of CV risks in each resident.
Indeed, when the Department of Healthcare Promo-
tion in Arita-cho routinely measured blood BNP and
adiponectin levels and performed echocardiograms
during its annual health care checkup of the resi-
dents, they found that the prevalence of hyper-
tension, diabetes, and dyslipidemia decreased within
10 years, compared with those of residents of neigh-
boring prefectures. This, in turn, decreased the cost
of medical care in Arita-cho compared with the
other areas.
EPIDEMIOLOGICAL INVESTIGATION OF
HEART FAILURE IN JAPAN
Despite these programs to reduce the prevalence of
risk factors, CVD occurs and can eventually cause
heart failure (HF). The issue that has gained attention
recently is heart failure with preserved ejection frac-
tion (HFpEF), which is tightly linked with the com-
ponents of the metabolic syndrome and aging (15), as
demonstrated by epidemiological studies. In the
United States, HFpEF is becoming more prominent
(16). In Japan, data collected from JCARE-CARD
(Japanese Cardiac Registry of Heart Failure inCardiology), a nationwide observational study,
showed that the rate of HFpEF has increased to about
30% among patients with HF (17,18). In addition,
when patients with HF with reduced ejection fraction
were compared with those with HFpEF, this study
reported that the prevalence of CV death, including
sudden death, was slightly higher in HF with reduced
ejection fraction (68% vs. 58%); HF death, the most
common cause of death, was similar between groups
(37% vs. 35%); and non-CV mortality was signiﬁcantly
higher in HFpEF (28% vs. 18%). Furthermore, 2 lon-
gitudinal observational studies—the CHART (Chronic
Heart Failure Analysis and Registry in the Tohoku
District)-1 in 2004 and CHART-2 in 2010 (19,20) eval-
uating HF patients in the Tohoku area in Japan—re-
ported several changes in the pathophysiology of HF,
and speciﬁcally, increases in the following: 1) the
prevalence of comorbidities, such as hypertension
(from 47% to 74%) and diabetes mellitus (from 20% to
23%); 2) the prevalence of ischemic heart failure from
26% to 47%; 3) the prevalence of obesity; 4) the
prevalence of HFpEF from 51% to 69%; and 5) HF
severity, gauged by plasma BNP levels. The reason for
the higher prevalence of HFpEF among patients in
Tohoku compared with those in JCARE-CARD may be
attributed to the high prevalence of hypertension in
the Tohoku area. Miura et al. (3) also pointed out that
physical activity and frailty were important de-
terminants of mortality and morbidity in patients
with HF (21), which could be explained by the
increased ratio of the aged population in Japan. In
our hospital cohort of HF patients, we found that the
lack of a spouse/partner and presence of constipation
and/or sleep disturbance in addition to cardiac
dysfunction were closely related to the rate of reho-
spitalization due to HF (22). Because Japan leads the
world with regard to an aging society, we should
focus not only on cardiac dysfunction but also on the
general condition of the entire body and the social
circumstances of the patient. All countries may
follow the pattern of CVD that Japan goes through in
advance. Therefore, Japan has a responsibility of
providing caution on how to avoid CVD in the older
population.
HOW TO SEEK THE NOVELTY BEYOND THE
STATISTICS OF EPIDEMIOLOGICAL BIG DATA?
On the basis of the results of epidemiological studies,
data from patients with CVD and HF are important for
primary, secondary, and tertiary prevention. The
signiﬁcant question is whether the primary purpose
for data collection is academic. The goal seems to
have been for epidemiological studies, but it would
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198be better to translate this clinically by seeking for
unknown factors, alone or in combination, to explain
CV events.
How do we do this type of analysis? One answer is
by using “data mining,” which is a technique of
obtaining unexpected information using methods of
data analysis, such as pattern recognition, artiﬁcial
intelligence, and statistics (23). These methods pro-
vide only the necessary conditions for candidates
that could explain the pathophysiology of CVD.
Simply speaking, all possible combinations of each
element are provided to explain outcomes. For
example, if there are 4 candidates (A, B, C, and D)
for CV events, data mining will test the effects of
A, B, C, D, A þ B, A þ C, A þ D, B þ C, B þ D, C þ D,
A þ B þ C, B þ C þ D, C þ D þ A, D þ A þ B, and
A þ B þ C þ D on CV events. Furthermore, we can
study all elements that do not seem to be superﬁcially
linked to CV events and test the combinations that are
linked to signiﬁcant CV events (24). This type of
analysis has not been possible in medicine. To in-
crease the analytical power and obtain convincing
results, we need to collect a lot more data. However,
the obtained results are still within the necessary
conditions and need to be tested whether they are
sufﬁcient.A PROPOSAL FOR NEW TRENDS
OF THE CLINICAL RESEARCH
Furthermore, to identify target molecules or drugs for
CVD treatment from a large medical database for basic
research, we need to narrow down the criteria and
validate the candidates that will fulﬁll the necessary
and sufﬁcient conditions between the target goals
and pathophysiology of CVD. Importantly, the effec-
tiveness of such molecules or drugs in clinical prac-
tice needs to be re-evaluated by large-scale clinical
trials. This cycle of clinical/basic/clinical studies,
along with data mining methods, constitutes the best
strategy for inventing novel drugs in the medical
ﬁeld, especially in cardiology.
Last but not least, to understand the current status
and future directions of CVD and HF, data collection
from patients with either CVD or HF, both with and
without CV risks, is encouraged nationwide, Asia-
wide, and worldwide.
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